Comparative Pharmacology
Head-to-head clinical analysis: ACHROMYCIN V versus ATRIDOX.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ACHROMYCIN V versus ATRIDOX.
ACHROMYCIN V vs ATRIDOX
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Bacteriostatic; binds reversibly to 30S ribosomal subunit, inhibits protein synthesis by blocking aminoacyl-tRNA binding to mRNA-ribosome complex.
ATRIDOX (doxycycline hyclate) is a tetracycline antibiotic that inhibits bacterial protein synthesis by binding to the 30S ribosomal subunit, preventing aminoacyl-tRNA from binding to the A site. It also exhibits anti-inflammatory effects by inhibiting matrix metalloproteinases (MMPs) and reducing cytokine production.
250-500 mg orally every 6 hours
50 mg subgingival controlled-release insert applied by dental professional into periodontal pockets once every 3 months.
None Documented
None Documented
Terminal elimination half-life is 6-12 hours in patients with normal renal function; prolonged in renal impairment (up to 48-72 hours in anuria).
Terminal half-life 16-18 hours; prolonged to 24-48 hours in renal impairment, requiring dose adjustment.
Renal (60% unchanged in urine via glomerular filtration), biliary/fecal (40% as active drug and metabolites, with a portion undergoing enterohepatic recirculation).
Primarily renal (60-70% unchanged), biliary/fecal (10-15%) as active drug and metabolites; remainder metabolized.
Category C
Category C
Tetracycline Antibiotic
Tetracycline Antibiotic